📰 Scienta Communications News
Page 2 - Scienta Communications News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Scienta Communications. Real-time updates on events, politics, business and more.
April 10, 2023
SAN DIEGO, April 10, 2023 -- Crinetics Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare... | April 10, 2023
February 28, 2023
Paltusotine’s Phase 3 PATHFNDR-1 study enrollment complete and topline data expected in 3Q 2023Paltusotine’s Phase 3 PATHFNDR-2 study enrollment ongoing with topline data now expected in... | February 28, 2023
February 11, 2023
10.02.2023 - SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and ...
February 10, 2023
SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the...
November 22, 2022
22.11.2022 - SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in a fireside chat and 1x1 investor meetings at the 5th Annual Evercore ISI HealthCONx Conference ...
November 21, 2022
Cognition Therapeutics Launches Neuroscience Thought Leader Conversations Podcast/Webinar Series - read this article along with other careers information, tips and advice on BioSpace
October 13, 2022
SAN DIEGO, Oct. 13, 2022 -- Crinetics Pharmaceuticals, Inc. today announced the completion of enrollment in the Phase 3 PATHFNDR-1 study. PATHFNDR-1 is one of two ongoing, placebo-controlled Phase... | October 13, 2022
October 3, 2022
SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the appointment of Dana Pizzuti, M.D., as...
October 3, 2022
Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer - read this article along with other careers information, tips and advice on BioSpace
September 6, 2022
06.09.2022 - PURCHASE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) - Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule ...